Smith+Nephew Appoints New Non-Executive Director

Smith & Nephew Snats ( (SNN) ) just unveiled an announcement.

Smith+Nephew announced the appointment of David King as an independent Non-Executive Director, effective July 1, 2025. King brings extensive experience in the healthcare and life sciences sectors, having held leadership roles at Fortis Life Sciences and Laboratory Corporation of America. His appointment is expected to enhance Smith+Nephew’s board with his expertise in transforming and growing businesses globally.

The most recent analyst rating on (SNN) stock is a Hold with a $27.27 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats is well-positioned due to strong financial performance and positive earnings call sentiment, highlighting growth and strategic execution. The technical analysis indicates a strong upward trend, although overbought conditions may pose short-term risks. The high P/E ratio suggests potential overvaluation, but the dividend yield adds some appeal for income-focused investors.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. With a mission to restore people’s bodies and self-belief, the company operates in around 100 countries and generated annual sales of $5.8 billion in 2024. It is a constituent of the FTSE100 and has three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Average Trading Volume: 848,589

Technical Sentiment Signal: Buy

Current Market Cap: $13.3B

See more insights into SNN stock on TipRanks’ Stock Analysis page.